Loading
In EPCORE NHL-1, the off-the-shelf bispecific antibody epcoritamab, injected under the skin, produced responses in 63% of 157 patients with relapsed large B-cell lymphoma, including the 39% whose CAR-T had failed. Cytokine release syndrome occurred in half, mostly mild, and the drug won accelerated approval in 2023.
The dose-expansion part of EPCORE NHL-1 treated 157 patients with relapsed or refractory large B-cell lymphoma after at least two prior lines (median three; 39% had prior CAR-T) with subcutaneous epcoritamab given with step-up dosing then weekly, fortnightly and monthly. The overall response rate was 63.1% with complete response in 38.9%; median duration of response was 12.0 months and complete responders had durable remissions. CRS occurred in 49.7% (grade 3 in 2.5%) and ICANS in 6.4% with one fatal event. Responses were similar after CAR-T failure. Epcoritamab received accelerated approval in 2023, alongside the intravenous CD20 x CD3 bispecific glofitamab, whose pivotal study reported complete response in 39% of 155 patients.
CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.
Shares EPCORE DLBCL-1, EPCORE NHL-1, STARGLO, Odronextamab.
Shares Odronextamab, Objective response rate (ORR), CD3, Cytokine release syndrome (CRS).
Shares STARGLO, Glofitamab, CD3, CD20.
Shares Odronextamab, CD3, CD20, Bispecific antibodies.
Shares Odronextamab, Mosunetuzumab, Epcoritamab, Glofitamab.
Shares CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab), Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Epcoritamab, Glofitamab, ICANS (neurotoxicity), Cytokine release syndrome (CRS).
Shares Mosunetuzumab, CD3, CD20, Bispecific antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/